High NUCB2 expression level is associated with metastasis and may promote tumor progression in colorectal cancer

Xie,Jun; Chen,Lina; Chen,Wenbin

doi:10.3892/ol.2018.8523

High NUCB2 expression level is associated with metastasis and may promote tumor progression in colorectal cancer

Authors:
- Jun Xie
- Lina Chen
- Wenbin Chen
View Affiliations

Affiliations: Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Department of Paediatrics, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang 312000, P.R. China
Published online on: April 18, 2018 https://doi.org/10.3892/ol.2018.8523
Pages: 9188-9194
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nucleobindin 2 (NUCB2) is mainly expressed in the hypothalamic nuclei and has a proven role in energy homeostasis. It has also been recently reported to have a key role in tumor progression. However, the clinical significance of NUCB2 in colorectal cancer (CRC) remains unknown. In the present study, the level of NUCB2 mRNA was quantified by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) in 34 paired fresh tissues from patients with CRC. RT‑qPCR was followed by immunohistochemical (IHC) staining of NUCB2 protein in tissue microarrays of 251 samples to evaluate the clinical significance of NUCB2 in CRC. The RT‑qPCR indicated an upregulation of NUCB2 mRNA in CRC tissues compared with normal tissues (P=0.027). IHC staining indicated a positive association between elevated NUCB2 expression and lymph node metastasis or tumor‑node‑metastasis (TNM) stage. Patients with CRC and lymph node metastasis demonstrated a higher expression of NUCB2 (49.5%, 50/101) compared with those without lymph node metastasis (36.7%, 55/150; P=0.043). Furthermore, NUCB2 expression was also higher in patients with CRC and TNM stage III‑IV compared with those with TNM stage I‑II (50.9% vs. 35.0%; P=0.011). However, Kaplan‑Meier analysis indicated no significant association between NUCB2 expression and disease‑free survival of patients. Additionally, multivariate analysis did not identify the upregulation of NUCB2 as an independent prognostic predictor in patients with CRC (P=0.755). In conclusion, the present study demonstrated that upregulation of NUCB2 is significantly associated with CRC metastasis, indicating that NUCB2 may be a cancer‑associated oncogene associated with the aggressive progression of CRC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Van Cutsem E and Oliveira J: ESMO Guidelines Working Group: Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20:61–63. 2009. View Article : Google Scholar : PubMed/NCBI
3	Yoo PS, Lopez-Soler RI, Longo WE and Cha CH: Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 6:202–207. 2006. View Article : Google Scholar : PubMed/NCBI
4	Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, et al: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 443:709–712. 2006. View Article : Google Scholar : PubMed/NCBI
5	Garcia-Galiano D, Navarro VM, Gaytan F and Tena-Sempere M: Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J Mol Endocrinol. 45:281–290. 2010. View Article : Google Scholar : PubMed/NCBI
6	Zhang H, Qi C, Li L, Luo F and Xu Y: Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res. 32:562013. View Article : Google Scholar : PubMed/NCBI
7	Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y and Xu Y: Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res. 32:772013. View Article : Google Scholar : PubMed/NCBI
8	Kan JY, Yen MC, Wang JY, Wu DC, Chiu YJ, Ho YW and Kuo PL: Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer. Oncotarget. 7:31336–31349. 2016. View Article : Google Scholar : PubMed/NCBI
9	Qi C, Ma H, Zhang HT, Gao JD and Xu Y: Nucleobindin 2 expression is an independent prognostic factor for clear cell renal cell carcinoma. Histopathology. 66:650–657. 2015. View Article : Google Scholar : PubMed/NCBI
10	Suzuki S, Takagi K, Miki Y, Onodera Y, Akahira J, Ebata A, Ishida T, Watanabe M, Sasano H and Suzuki T: Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 103:136–143. 2012. View Article : Google Scholar : PubMed/NCBI
11	Ramanjaneya M, Tan BK, Rucinski M, Kawan M, Hu J, Kaur J, Patel VH, Malendowicz LK, Komarowska H, Lehnert H, et al: Nesfatin-1 inhibits proliferation and enhances apoptosis of human adrenocortical H295R cells. J Endocrinol. 226:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
12	Xu Y, Pang X, Dong M, Wen F and Zhang Y: Nesfatin-1 inhibits ovarian epithelial carcinoma cell proliferation in vitro. Biochem Biophys Res Commun. 440:467–472. 2013. View Article : Google Scholar : PubMed/NCBI
13	Edge SB and Compton CC: The American Joint Committie on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Haggar FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
16	Field K and Lipton L: Metastatic colorectal cancer-past, progress and future. World J Gastroenterol. 13:3806–3815. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kraljevic Pavelic S, Sedic M, Bosnjak H, Spaventi S and Pavelic K: Metastasis: New perspectives on an old problem. Mol Cancer. 10:222011. View Article : Google Scholar : PubMed/NCBI
18	Cao X, Liu XM and Zhou LH: Recent progress in research on the distribution and function of NUCB2/nesfatin-1 in peripheral tissues. Endocr J. 60:1021–1027. 2013. View Article : Google Scholar : PubMed/NCBI
19	Takagi K, Miki Y, Tanaka S, Hashimoto C, Watanabe M, Sasano H, Ito K and Suzuki T: Nucleobindin 2 (NUCB2) in human endometrial carcinoma: A potent prognostic factor associated with cell proliferation and migration. Endocr J. 63:287–299. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhang H, Qi C, Wang A, Li L and Xu Y: High expression of nucleobindin 2 mRNA: An independent prognostic factor for overall survival of patients with prostate cancer. Tumour Biol. 35:2025–2028. 2014. View Article : Google Scholar : PubMed/NCBI
21	Yang M, Zhang Z, Wang C, Li K, Li S, Boden G, Li L and Yang G: Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance. Diabetes. 61:1959–1968. 2012. View Article : Google Scholar : PubMed/NCBI
22	Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Wang Z, Xie H, Dai B, Xu J and Ye D: High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients. Oncotarget. 8:35244–35254. 2017.PubMed/NCBI
23	Kaplan MA, Isikdogan A, Gumus M, Arslan UY, Geredeli C, Ozdemir N, Koca D, Dane F, Suner A, Elkiran ET, et al: Childhood, adolescents, and young adults (≤25 y) colorectal cancer: Study of Anatolian Society of Medical Oncology. J Pediatr Hematol Oncol. 35:83–89. 2013. View Article : Google Scholar : PubMed/NCBI
24	Zhao L, Bao F, Yan J, Liu H, Li T, Chen H and Li G: Poor prognosis of young patients with colorectal cancer: A retrospective study. Int J Colorectal Dis. 32:1147–1156. 2017. View Article : Google Scholar : PubMed/NCBI
25	Taggarshe D, Rehil N, Sharma S, Flynn JC and Damadi A: Colorectal cancer: Are the ‘young’ being overlooked? Am J Surg. 205:312–316. 2013. View Article : Google Scholar : PubMed/NCBI
26	Yeo SA, Chew MH, Koh PK and Tang CL: Young colorectal carcinoma patients do not have a poorer prognosis: A comparative review of 2,426 cases. Tech Coloproctol. 17:653–661. 2013. View Article : Google Scholar : PubMed/NCBI
27	You YN, Xing Y, Feig BW, Chang GJ and Cormier JN: Young-onset colorectal cancer: Is it time to pay attention? Arch Intern Med. 172:287–289. 2012. View Article : Google Scholar : PubMed/NCBI
28	Ashktorab H, Paydar M, Namin HH, Sanderson A, Begum R, Brim H, Panchal H, Lee E, Kibreab A, Nouraie M and Laiyemo AO: Prevalence of colorectal neoplasia among young African Americans and hispanic Americans. Dig Dis Sci. 59:446–450. 2014. View Article : Google Scholar : PubMed/NCBI